Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Plans underway to expand screening capacity by 50% for greater accessibility
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Pflow is a revolutionary, disposable, and portable home based urine flow measurement test
The trademark rights for these brands will be transferred to Lupin by March next year.
Subscribe To Our Newsletter & Stay Updated
